GlassScriptPhysician profile
Jeremy T Diver
NPI 1679913354
$2,674.63
in general payments reported to CMS, 2019-2025
19 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $835 · 2023: $1,164 · 2024: $364 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.58 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $304.41 | 2022 | |
| Novo Nordisk INC | $280.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $253.03 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $203.07 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $198.75 | 2022-2024 | |
| Abbott Laboratories | $151.25 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $142.95 | 2022-2023 | Farxiga |
| Exact Sciences Corporation | $109.50 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $92.25 | 2023-2025 | |
| Amgen INC. | $59.65 | 2021-2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $41.25 | 2023 | Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.12 | 2022-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $22.61 | 2024 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $20.01 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $17.22 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.69 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.05 | 2022 | |
| Amarin Pharma, INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Diver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.